title: Re: Orazio Caffo, Ugo De Giorgi, Lucia Fratino, et al. Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. Eur Urol 2015;68:147-53.
authors: School of Medicine, I-Shou University, Kaohsiung City, Taiwan; Division of Urology, Department of Surgery, E-Da Hospital, Kaohsiung City, Taiwan; Division of Urology, E-Da Cancer Hospital, Kaohsiung City, Taiwan. Electronic address: kevinlu0620@mail2000.com.tw.
authors: Kevin
authors: K
authors: Lu
mesh_terms: D000069501:Abiraterone Acetate / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D010669:Phenylthiohydantoin / Q000031:analogs & derivatives*; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy*; D043823:Taxoids / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D043823:Taxoids; D010669:Phenylthiohydantoin; D000069501:Abiraterone Acetate